2026 Q3 Portfolio Activity
In 2026 Q3, Logos Global Management LP maintained a portfolio of 96 distinct positions. The most significant new addition was MADRIGAL PHARMACEUTICALS INC, now representing 2.71% of the total fund value. They heavily accumulated shares in PRAXIS PRECISION MEDICINES I, increasing the position by 63.5%. The fund also reduced its exposure to ERASCA INC by 79.4%.
Position History
hover any row below to update
Loading…
Total Positions
96
Quarter
2026 Q3
Top Holding
PRAX (6.7%)
Top 10 Concentration
44.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 96
Logos Global Management LP Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 6.67% | 3.75% |
#1
7
Prev: #8
|
7.7 |
—
|
165,000 | 63.5% |
P
S
|
425,000 | $123,772,750 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 6.63% | 5.64% |
#2
1
Prev: #3
|
4.7 |
—
|
-100,000 | -14.3% |
P
S
|
600,000 | $123,156,000 | 2020 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IDYA
IDEAYA BIOSCIEN...
|
Healthcare | 5.90% | 4.81% |
#3
1
Prev: #4
|
3.9 |
—
|
-150,000 | -5.0% |
P
S
|
2,850,000 | $109,497,000 | 2021 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ERAS
ERASCA INC
|
Healthcare | 4.66% | 9.58% |
#4
3
Prev: #1
|
2.4 |
—
|
-6,250,000 | -51.4% |
P
S
|
5,900,000 | $86,494,000 | 2024 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 4.64% | 5.87% |
#5
3
Prev: #2
|
2.9 |
—
|
-154,000 | -15.0% |
P
S
|
870,000 | $86,147,400 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 3.72% | 3.06% |
#6
5
Prev: #11
|
2.0 |
—
|
-25,000 | -2.5% |
P
S
|
975,000 | $69,117,750 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 3.58% | 2.76% |
#7
5
Prev: #12
|
3.4 |
—
|
140,000 | 16.0% |
P
S
|
1,015,000 | $66,441,900 | 2023 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BNTX
BIONTECH SE
|
Healthcare | 3.44% | 4.07% |
#8
3
Prev: #5
|
1.4 |
—
|
-365,000 | -36.0% |
P
S
|
650,000 | $63,895,000 | 2020 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 2.89% | 3.84% |
#9
2
Prev: #7
|
1.2 |
—
|
-700,000 | -24.6% |
P
S
|
2,150,000 | $53,642,500 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MDGL
MADRIGAL PHARMA...
|
Healthcare | 2.71% | — |
#10
Prev: #—
|
4.6 |
—
|
100,000 | — |
NEW
|
100,000 | $50,396,000 | 2019 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 2.67% | 1.02% |
#11
21
Prev: #32
|
4.1 |
—
|
615,000 | 132.3% |
P
S
|
1,080,000 | $49,507,200 | 2023 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 2.60% | 2.44% |
#12
2
Prev: #14
|
3.0 |
—
|
450,000 | 17.6% |
P
S
|
3,000,000 | $48,330,000 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 2.48% | 2.24% |
#13
3
Prev: #16
|
3.0 |
—
|
700,000 | 13.2% |
P
S
|
6,000,000 | $46,020,000 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 2.37% | 3.36% |
#14
4
Prev: #10
|
0.9 |
—
|
-300,000 | -37.5% |
P
S
|
500,000 | $44,025,000 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AVBP
ARRIVENT BIOPHA...
|
Healthcare | 2.20% | 1.50% |
#15
8
Prev: #23
|
3.4 |
—
|
350,000 | 35.0% |
P
S
|
1,350,000 | $40,878,000 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 2.16% | 1.50% |
#16
6
Prev: #22
|
3.4 |
—
|
350,000 | 38.9% |
P
S
|
1,250,000 | $40,025,000 | 2020 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ERAS
CALL
ERASCA INC
|
CALL Option | 1.97% | — |
#17
Prev: #—
|
4.3 |
—
|
2,500,000 | — |
NEW
|
2,500,000 | $36,650,000 | 2024 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NBIX
NEUROCRINE BIOS...
|
Healthcare | 1.91% | — |
#18
Prev: #—
|
4.3 |
—
|
250,000 | — |
NEW
|
250,000 | $35,460,000 | 2022 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BLTE
BELITE BIO INC
|
Healthcare | 1.83% | 1.66% |
#19
Prev: #19
|
0.7 |
—
|
-50,000 | -20.0% |
P
S
|
200,000 | $33,964,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 1.74% | — |
#20
Prev: #—
|
4.2 |
—
|
175,000 | — |
NEW
|
175,000 | $32,268,250 | 2019 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 1.68% | 1.16% |
#21
8
Prev: #29
|
3.7 |
—
|
500,000 | 100.0% |
P
S
|
1,000,000 | $31,270,000 | 2023 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
OLMA
OLEMA PHARMACEU...
|
Healthcare | 1.49% | 1.73% |
#22
4
Prev: #18
|
1.6 |
—
|
no change | no change |
P
S
|
3,208,875 | $27,724,680 | 2020 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ACHV
ACHIEVE LIFE SC...
|
Healthcare | 1.39% | 1.53% |
#23
3
Prev: #20
|
0.6 |
—
|
-2,225,000 | -41.0% |
P
S
|
3,200,000 | $25,888,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 1.37% | 2.49% |
#24
11
Prev: #13
|
0.5 |
—
|
-1,000,000 | -51.7% |
P
S
|
935,000 | $25,413,300 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PBLS
PARABILIS MEDIC...
|
Healthcare | 1.30% | 0.62% |
#25
18
Prev: #43
|
3.0 |
—
|
225,000 | 42.9% |
P
S
|
750,000 | $24,217,500 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
APMD
APNIMED INC
|
Healthcare | 1.30% | — |
#26
Prev: #—
|
4.0 |
—
|
1,100,000 | — |
NEW
|
1,100,000 | $24,101,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
YARW
YARROW BIOSCIEN...
|
Healthcare | 1.25% | — |
#27
Prev: #—
|
4.0 |
—
|
1,026,258 | — |
NEW
|
1,026,258 | $23,111,330 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AVTX
CALL
AVALO THERAPEUT...
|
CALL Option | 1.24% | — |
#28
Prev: #—
|
4.0 |
—
|
1,500,000 | — |
NEW
|
1,500,000 | $22,995,000 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 1.11% | 1.51% |
#29
8
Prev: #21
|
0.4 |
—
|
-435,000 | -23.1% |
P
S
|
1,445,000 | $20,692,400 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MANE
VERADERMICS INC
|
Healthcare | 1.11% | 0.95% |
#30
3
Prev: #33
|
0.9 |
—
|
-10,000 | -5.6% |
P
S
|
170,000 | $20,609,100 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
REPL
CALL
REPLIMUNE GROUP...
|
CALL Option | 1.07% | — |
#31
Prev: #—
|
3.9 |
—
|
1,500,000 | — |
NEW
|
1,500,000 | $19,860,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 1.04% | 4.06% |
#32
26
Prev: #6
|
0.4 |
—
|
-1,600,000 | -72.7% |
P
S
|
600,000 | $19,374,000 | 2021 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DSGN
CALL
DESIGN THERAPEU...
|
CALL Option | 1.02% | — |
#33
Prev: #—
|
3.9 |
—
|
1,500,000 | — |
NEW
|
1,500,000 | $18,855,000 | 2021 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SRPT
CALL
SAREPTA THERAPE...
|
CALL Option | 0.98% | — |
#34
Prev: #—
|
3.9 |
—
|
1,000,000 | — |
NEW
|
1,000,000 | $18,220,000 | 2019 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SRPT
SAREPTA THERAPE...
|
Healthcare | 0.98% | — |
#35
Prev: #—
|
3.9 |
—
|
1,000,000 | — |
NEW
|
1,000,000 | $18,220,000 | 2019 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 0.95% | 2.24% |
#36
21
Prev: #15
|
0.4 |
—
|
-1,175,000 | -43.9% |
P
S
|
1,500,000 | $17,550,000 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SMMT
CALL
SUMMIT THERAPEU...
|
CALL Option | 0.91% | — |
#37
Prev: #—
|
3.9 |
—
|
1,000,000 | — |
NEW
|
1,000,000 | $16,910,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IMCR
IMMUNOCORE HLDG...
|
Healthcare | 0.82% | 0.82% |
#38
1
Prev: #37
|
0.8 |
—
|
-100,000 | -16.7% |
P
S
|
500,000 | $15,145,000 | 2022 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BHVN
BIOHAVEN LTD
|
Healthcare | 0.79% | — |
#39
Prev: #—
|
3.8 |
—
|
1,100,000 | — |
NEW
|
1,100,000 | $14,685,000 | 2019 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CRSP
CRISPR THERAPEU...
|
Healthcare | 0.75% | 0.70% |
#40
1
Prev: #41
|
0.8 |
—
|
-50,000 | -16.7% |
P
S
|
250,000 | $13,830,000 | 2020 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BHVN
CALL
BIOHAVEN LTD
|
CALL Option | 0.72% | — |
#41
Prev: #—
|
3.8 |
—
|
1,000,000 | — |
NEW
|
1,000,000 | $13,350,000 | 2019 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 0.72% | 0.16% |
#42
16
Prev: #58
|
3.3 |
—
|
270,000 | 337.5% |
P
S
|
350,000 | $13,321,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RCUS
CALL
ARCUS BIOSCIENC...
|
CALL Option | 0.70% | — |
#43
Prev: #—
|
3.8 |
—
|
500,000 | — |
NEW
|
500,000 | $12,915,000 | 2023 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ENTX
ENTERA BIO LTD
|
Healthcare | 0.69% | — |
#44
Prev: #—
|
3.8 |
—
|
4,411,764 | — |
NEW
|
4,411,764 | $12,838,233 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DSGN
DESIGN THERAPEU...
|
Healthcare | 0.68% | 1.87% |
#45
28
Prev: #17
|
0.3 |
—
|
-2,000,000 | -66.7% |
P
S
|
1,000,000 | $12,570,000 | 2021 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CMPS
CALL
COMPASS PATHWAY...
|
CALL Option | 0.67% | — |
#46
Prev: #—
|
3.8 |
—
|
1,000,000 | — |
NEW
|
1,000,000 | $12,440,000 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
CRESCENT BIOPHA...
|
|
Unknown | 0.67% | 1.47% |
#47
23
Prev: #24
|
0.3 |
—
|
-1,050,000 | -55.3% |
P
S
|
850,000 | $12,401,500 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
ETRA
ELECTRA THERAPE...
|
Healthcare | 0.61% | — |
#48
Prev: #—
|
3.7 |
—
|
1,000,000 | — |
NEW
|
1,000,000 | $11,250,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NERV
MINERVA NEUROSC...
|
Healthcare | 0.59% | 0.79% |
#49
10
Prev: #39
|
1.2 |
—
|
no change | no change |
P
S
|
3,288,777 | $11,017,403 | 2019 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 0.52% | 0.82% |
#50
12
Prev: #38
|
0.2 |
—
|
-335,000 | -57.3% |
P
S
|
250,000 | $9,595,000 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-50 of 96 holdings